An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet recovery and helped patients with gastrointestinal cancers maintain platelet counts needed to continue chemotherapy as scheduled, according to results from a phase 2 clinical trial led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and Mass General Hospital.

An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet recovery and helped patients with gastrointestinal cancers maintain platelet counts ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC) tissues, identifying specific macrophage subtypes associated with chemotherapy response.